Clover Biopharmaceuticals, Ltd. (HKG:2197)

Market Cap	2.40B -11.8%
Revenue (ttm)	496.42K -99.2%
Net Income	982.63M
EPS	0.77
Shares Out	1.30B
PE Ratio	2.40
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,958,000
Open	1.850
Previous Close	1.880
Day's Range	1.840 - 1.925
52-Week Range	1.320 - 3.200
Beta	2.57
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 25, 2026

About Clover Biopharmaceuticals

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China and internationally. The company’s product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza; and SCB-219M, a thrombocytopenia receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia. It is also developing SCB-2023B ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 257
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2197

Financial Performance

In 2025, Clover Biopharmaceuticals's revenue was 3.51 million, a decrease of -90.88% compared to the previous year's 38.42 million. Losses were -205.09 million, -77.30% less than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 1, 2026

Data Sources Report a data error